Cladis Investment Advisory’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cladis Investment Advisory’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-80,000	Closed	-$32.3K	–	146
2023 Q1	$32.3K	Sell	80,000 -70,000	-47%	-$29.9K	0.03%	135
2022 Q4	$65.3K	Sell	150,000 -402,000	-73%	-$130K	0.06%	128
2022 Q3	$155K	Sell	552,000 -185,000	-25%	-$63.4K	0.17%	118
2022 Q2	$265K	Sell	737,000 -509,000	-41%	-$211K	0.27%	106
2022 Q1	$835K	Buy	1,246,000 +42,000	+3%	+$35.7K	0.68%	46
2021 Q4	$1.55M	Buy	+1,204,000	New	+$2.14M	1.25%	21

Other funds holding SIOX

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cladis Investment Advisory's SIOX Position: Q2 2023 in Review

Cladis Investment Advisory sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2023, closing a stake of 80,000 shares — an estimated $32.3K sold.

Cladis Investment Advisory first reported a position in SIOX in Q4 2021 and held it in 6 quarters. The position peaked at $1.55M in Q4 2021. 1 fund tracked by Wall St. Rank holds SIOX as of Q2 2023.

Cladis Investment Advisory reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cladis Investment Advisory sold 80,000 Sio Gene Therapies Inc. Common Stock shares in Q2 2023, an estimated $32.3K.
Cladis Investment Advisory first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Cladis Investment Advisory's Sio Gene Therapies Inc. Common Stock position peaked at $1.55M in Q4 2021.
1 fund tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2023.

Based on Cladis Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.